Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : 2011 Biotech Charity Contest -- Ignore unavailable to you. Want to Upgrade?

To: Jibacoa who wrote (230)	7/7/2011 8:26:14 AM
From: Biotech Jim	Respond to of 400

I have followed SNMX for the past few years as they seemed to have pretty good GPCR screening technology. However, there is a major league difference in the business model compared to the innovator small molecule discovery companies compared to the "food additives/flavor enhancer" companies. For biotech and pharma, the margins on an approved small molecule product is usually greater than 90-98%, when one takes into account point of sale cost. It is much lower for "food additives/flavor enhancer" company, so cost of goods would be a big issue. No current position in SNMX, but I have held it in the past. BJ

To: Jibacoa who wrote (230)	7/7/2011 9:57:20 AM
From: A.J. Mullen	Respond to of 400

Insider selling is always worrying. I paused for thought before buying when reading about an ostentatious car (Ferrari or some sort) owned by a senior executive. At the time I decided that's just a symptom of the compensation of executives in start-ups, but maybe those tastes lead to selling at inopportune times. I increased my holding to half a unit when the Pepsi deal was announced. I expected much more of a pop on that news. The prices seems to have moved more on SNMX's inclusion in the Russel 2000 and 3000 indices. Jim, I don't know what their profit margins will be. Maybe less than pharma, but high nevertheless. I think of SNMX's enhancers as levers for sugar or salt. They will have many more consumers than for any pharmaceutical. Ashley